Active Ingredient History
Hypromellose is a semisynthetic, inert, viscoelastic methyl and hydroxypropyl mixed ether of cellulose used as eye drops, as well as an excipient and controlled-delivery component in oral medicaments, found in a variety of commercial products. Hypromellose is considered an inert substance as it has no direct pharmacological activity. The viscosity promoting properties of hypromellose prolong the retention time and improve adhesion of synthetic tears to the cornea and conjunctiva. As a result, the tear film breakdown time is prolonged and/or the tear film stability is enhanced. A stable tear film protects the cornea from dryness Hypromellose is the most commonly used in hydrophilic matrix fabrication. Hypromellose provides the release of a drug in a controlled manner, effectively increasing the duration of release of a drug to prolong its therapeutic effect. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Cataract (Phase 4)
Conjunctivitis (Phase 4)
Conjunctivitis, Allergic (Phase 4)
Constipation (Phase 2)
Corneal Diseases (Phase 4)
Corneal Edema (Phase 4)
Dry Eye Syndromes (Phase 4)
Excipients ()
Eye Diseases (Phase 1)
Eye Infections (Phase 4)
Fatty Liver (Phase 1/Phase 2)
Glaucoma (Phase 4)
Graves Ophthalmopathy (Phase 4)
Intestinal Neoplasms (Phase 2)
Intraocular Pressure (Phase 4)
Keratoconus (Phase 1/Phase 2)
Lacrimal Apparatus Diseases (Phase 1)
Liver Cirrhosis (Phase 1/Phase 2)
Macular Edema (Phase 4)
Neoplasms (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 1/Phase 2)
Ocular Hypertension (Phase 4)
Postoperative Complications (Phase 4)
Prostatic Neoplasms (Phase 4)
Retinal Diseases (Phase 2/Phase 3)
Rhinitis, Allergic (Phase 2)
Rhinitis, Allergic, Seasonal (Phase 4)
Rosacea (Phase 2)
Uveitis, Anterior (Phase 4)
Varicella Zoster Virus Infection (Phase 2)
Vision, Ocular (Phase 1)
Vitreoretinopathy, Proliferative (Phase 2/Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue